Comparison

ZLN024 (hydrochloride)

Item no. CS-3463-5mg
Manufacturer ChemScene
Amount 5mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Available
Purity
>98%
Formula
C13H14BrClN2OS
MWt
361.69
Solubility
DMSO : >= 46 mg/mL (127.18 mM)
Clinical Information
No Development Reported
Pathway
Epigenetics; PI3K/Akt/mTOR
Target
AMPK; AMPK
Biological Activity
ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK alpha1beta1gamma1, AMPK alpha2beta1gamma1, AMPK alpha1beta2gamma1 and AMPK alpha2beta2gamma1 heterotrimer with EC50s of 0.42 uM, 0.95 uM, 1.1 uM and 0.13 uM, respectively. IC50 & Target: EC50: 0.42 uM, 0.95 uM, 1.1 uM and 0.13 uM (AMPK alpha1beta1gamma1, alpha2beta1gamma1, alpha1beta2gamma1 and alpha2beta2gamma1 heterotrimer)[1] In Vitro: ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive alpha1 subunit truncations alpha1 (1-394) and alpha1 (1-335) but not alpha1 (1-312). AMPK activation by ZLN024 requires the pre-phosphorylation of Thr-172 by at least one upstream kinase and protects AMPK Thr-172 against dephosphorylation by PP2Calpha. ZLN024 activates AMPK in L6 myotubes and stimulates glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. Using the established scintillation proximity assay (SPA) assay, random screening against the AMPK alpha1beta1gamma1 heterotrimer is performed and a new AMPK activator, ZLN024 is found. ZLN024 directly activates recombinant AMPK alpha1beta1gamma1 and its homologue alpha2beta1gamma1 in a concentration-dependent manner. ZLN024 increases the activity of alpha1beta1gamma1 by 1.5-fold and has an EC50 of 0.42 uM, and it increases the activity of alpha2beta1gamma1 by 1.7-fold with an EC50 of 0.95 uM. ZLN024 also directly activates recombinant AMPK alpha1beta2gamma1, by 1.7-fold with an EC50 of 1.1 uM; and AMPK alpha2beta2gamma1, by 1.6-fold with an EC50 of 0.13 uM[1]. In Vivo: C57BKS db/db mice are administered a 15 mg/kg/day dose of ZLN024 by daily gavage for 5 weeks; 250 mg/kg/day Metformin (Met) is used as a positive control. During the treatment period, there is no significant alteration in food intake and body weight compared with the vehicle group. After 4 weeks of treatment, ZLN024 improves glucose tolerance. ZLN024 reduces the fasting blood glucose by 15%. Liver tissue weight, triacylglycerol and the total cholesterol content are decreased[1].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close